Furui: Kangfang Biotech (09926) obtained positive results in the evosimab H-2 study maintained a “buy” rating

The Zhitong Finance App learned that Jefferies released a research report saying that the Kangfang Biotech (09926) Ivonescimab (Ivonescimab) H-2 study obtained positive results. The data showed that the median overall survival (OS) was statistically significant, and first-line treatment of PD-L1 positive non-small cell lung cancer with a single drug significantly lengthened the OS compared to pembrolizumab (Pembrolizumab). The bank believes that evosimab has an overall survival advantage. The data is encouraging, maintaining Kangfang Biotech's “buy” rating and target price of HK$226. The data showed that the median OS in the evosimab group was 30.8 months, the risk ratio was 0.73, and the median follow-up was 36 months; the median OS in the pabolizumab group was 22.6 months.